Appointment of Clarissa Desjardins and renewal of Robert Paré and Jacques Bernier’s mandate on the IRIC’s Board of Directors

Published on June 3, 2021

IRIC is pleased to announce the appointment of Clarissa Desjardins as a new member of the Board of Directors as well as the renewal of Mtre Robert Paré and Mr. Jacques Bernier’s mandate as a member of the Board by the Executive Committee of the Université de Montréal.

Dr. Desjardins was previously the President and CEO of Clementia Pharmaceuticals Inc., CEO at the Center of Excellence in Personalized Medicine, founder of Advanced Bioconcept and co-founded Caprion Pharmaceuticals Inc.

Clarissa Desjardins is the recipient of the 2018 Bloom Burton Award for her contribution to Canada’s innovative healthcare industry, the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of 2017’s Fiercest Women in Life Sciences by FiercePharma. She committed to IRIC for a three-year mandate.

“We are proud to welcome Dr. Desjardins as a member of IRIC’s Board of Directors. She is a woman who has distinguished herself through her career, demonstrating great versatility and possessing remarkable expertise in both the research sector and its translation to commercial value,” says Michel Bouvier, IRIC’s Executive Director.

Mtre Robert Paré, Strategic Advisor with Fasken, recognized as one of the leading corporate lawyers in Canada, will begin his second mandate on the Institute’s Board of Directors on June 1st, 2021, for a period of three years.

Jacques Bernier, Managing Partner at Teralys Capital and former Senior Vice-President of the Fonds de solidarité FTQ, will begin his third mandate on the Institute’s Board of Directors on September 18th, 2021, for a period of three years.

IRIC is delighted to count on their support and would particularly like to thank them for their commitment to the cause.